STAT reports that preliminary results from a study in Chicago evaluating Gilead Sciences’ (NASDAQ:GILD)
remdesivir in severely ill COVID-19 patients are positive with rapid
recoveries in fever and respiratory symptoms observed and almost all
patients discharged in less than a week.
The news is lifting shares, up 6% after hours, a welcome bit of good news on the heels of two canceled studies in China due to low enrollment.
https://seekingalpha.com/news/3561503-gilead-up-6-after-hours-on-remdesivir-buzz-in-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.